Welcome to our dedicated page for Sophia Genetics Sa SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
SOPHiA GENETICS SA (SOPH) filed a Form 144 indicating that Ross J. Muken intends to sell up to 14,509 common shares through Morgan Stanley Smith Barney on or about 20 June 2025. At the most recent market price reflected in the filing, the shares have an aggregate value of $44,107.36. The company has 66,687,085 shares outstanding, meaning the proposed sale represents roughly 0.02 % of shares outstanding.
The filing also discloses that, under a Rule 10b5-1 trading plan, Muken has sold 14,542 shares in the prior three months for total gross proceeds of approximately $40,660. The current notice confirms the seller’s representation that no undisclosed material adverse information is known at the time of the planned sale.
Because the transaction size is modest relative to the company’s share count and is executed under a pre-arranged trading plan, the filing is routine and unlikely to have a material impact on SOPH’s capital structure or stock liquidity.